SCHEMBL2651789

SCHEMBL2651789

Cc1cccc(NC(=O)NC(c2ccc(C(=O)NCCC(=O)O)cc2)c2ccc(C3=CCCCC3)cc2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCGR P47871 14/20 0.49
GIPR P48546 8/20 0.49
GLP1R P43220 1/20 0.49
GAA P10253 2/20 0.43
MAPT P10636 2/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
CCKBR P32239 1/20 0.40
ADCY6 O43306 1/20 0.40
ADCY3 O60266 1/20 0.40
ADCY9 O60503 1/20 0.40
ADCY5 O95622 1/20 0.40
ADCY8 P40145 1/20 0.40
ADCY7 P51828 1/20 0.40
ADCY2 Q08462 1/20 0.40
ADCY1 Q08828 1/20 0.40
ADCY4 Q8NFM4 1/20 0.40
SLC6A9 P48067 1/20 0.39
SLC6A5 Q9Y345 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2651200 0.92 GCGR (0.49) GCGRGIPRGLP1RGAAMAPT
SCHEMBL2650187 0.90 GCGR (0.54) GCGRGIPRGLP1RMAPTSMN1; SMN2
SCHEMBL2651224 0.90 GCGR (0.49) GCGRGIPRGLP1RGAAMAPT
SCHEMBL2651843 0.90 GCGR (0.49) GCGRGIPRGLP1RMAPTHTT
SCHEMBL2650113 0.90 GCGR (0.57) GCGRGIPRGLP1RMAPTSMN1; SMN2
SCHEMBL6752839 0.90 GCGR (0.49) GCGRGIPRGLP1RSMN1; SMN2ADCY6
SCHEMBL6750344 0.90 GCGR (0.49) GCGRGIPRGLP1RADCY6ADCY3
SCHEMBL6752430 0.89 GCGR (0.47) GCGRGIPRGLP1RGAAMAPT
SCHEMBL2651922 0.88 NPSR1 (0.50) GCGRGIPRGLP1RGAAMAPT
SCHEMBL6751674 0.88 SMN1; SMN2 (0.50) GCGRGIPRGLP1RGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040127560-A1 Glucagon antagonists/inverse agonists MADSEN PETER (DK) 2004-07-01 US claimed
US-6706744-B2 HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS NOVO NORDISK A/S (DK) 2004-03-16 US claimed
US-20030065031-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-04-03 US claimed
WO-2002040444-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2002-05-23 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127560-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885GIPR 4/4885GLP1R 1/4885
US-20030065031-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885GIPR 4/4885GLP1R 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.